A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy

Completed · Phase 1/Phase 2

Conditions studied: Lung Neoplasms

In brief

The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the treatment of advanced stage non-small cell lung cancer.

Key facts

Study ID

NCT00074854

Run by

Pfizer

People needed

87

Starts

2002-05-01

Expected to finish

2005-03-01

Last updated by the study team

2006-11-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed stage IIIB (inicluding those with pleural effusion), IV or recurrent non-small cell lung cancer (nsclc).
• Bidimensionally measurable disease >2cm x 1 cm by conventional CT Scan or >1 cm x 1cm by spiral CT Scan.

You may not qualify if…

• No tumors in close proximity to major veins or arteries.
• No sanguinous pleural effusion due to disease or pericardial effusion suspicious for disease.
• No evidence or history brain metastases.

Where it is running

• Pfizer Investigational Site — Greenbrae, California, United States
• Pfizer Investigational Site — San Mateo, California, United States
• Pfizer Investigational Site — San Pablo, California, United States
• Pfizer Investigational Site — Tampa, Florida, United States
• Pfizer Investigational Site — Covington, Louisiana, United States
• Pfizer Investigational Site — Metairie, Louisiana, United States
• Pfizer Investigational Site — Metairie, Louisiana, United States
• Pfizer Investigational Site — New Orleans, Louisiana, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Stony Brook, New York, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Gallatin, Tennessee, United States
• Pfizer Investigational Site — Hermitage, Tennessee, United States
• Pfizer Investigational Site — Lebanon, Tennessee, United States
• Pfizer Investigational Site — Murfreesboro, Tennessee, United States
• Pfizer Investigational Site — Nashville, Tennessee, United States
• Pfizer Investigational Site — Nashville, Tennessee, United States
• Pfizer Investigational Site — Nashville, Tennessee, United States
• Pfizer Investigational Site — Nashville, Tennessee, United States
• Pfizer Investigational Site — Smyrna, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.